49. 全身性エリテマトーデス Systemic lupus erythematosus Clinical trials / Disease details
臨床試験数 : 993 / 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05666336 (ClinicalTrials.gov) | December 31, 2022 | 8/12/2022 | Multi-omics Studies on the Efficacy of Telitacicept in Chinese SLE Patients | Proteomics Combined With Metabolomics Studies on the Efficacy of Telitacicept in Chinese Patients of Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | Biological: Telitacicept;Drug: Hydroxychloroquine;Drug: Prednisone;Drug: Methylprednisolone;Drug: Cyclophosphamide;Drug: Mycophenolate Mofetil;Drug: Tacrolimus | Fen Li | NULL | Not yet recruiting | 18 Years | 75 Years | All | 30 | Phase 4 | NULL |
| 2 | NCT05339217 (ClinicalTrials.gov) | July 1, 2022 | 2/4/2022 | Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus Erythematosus | Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus Erythematosus: a Randomise Prospective Study | Systemic Lupus Erythematosus | Drug: Telitacicept;Drug: Interleukin-2 | Peking University People's Hospital | NULL | Recruiting | 18 Years | 65 Years | All | 60 | Phase 3 | China |
| 3 | NCT05306574 (ClinicalTrials.gov) | June 20, 2022 | 23/3/2022 | A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Stage Trial to Evaluate Efficacy and Safety of Telitacicept Compared to Placebo in Patients With Moderately to Severely Active Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | Drug: Telitacicept;Drug: Placebo | RemeGen Co., Ltd. | NULL | Recruiting | 12 Years | 70 Years | All | 341 | Phase 3 | United States;Bulgaria;Colombia;Poland;Puerto Rico |
| 4 | NCT05247203 (ClinicalTrials.gov) | May 17, 2022 | 26/1/2022 | Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus | A Phase I, Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Telitacicept in Chinese Subjects With Systemic Lupus Erythematosus (SLE) | Systemic Lupus Erythematosus | Biological: Telitacicept;Drug: standard therapy | RemeGen Co., Ltd. | NULL | Recruiting | 18 Years | 65 Years | All | 75 | Phase 1 | China |